VYNE Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Adoption, Modification and Termination of Rule 10b5-1 Plans and Certain Other Trading Arrangements
During the three months ended September 30, 2024, none of our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended)adopted orterminated any contracts, instructions or written plans for the purchase or sale of our securities.
Inducement Plan Amendment
As of November 6, 2024, 131,907 shares remained available for issuance under the 2023 Plan. In addition, the Board reduced the number of shares available to be issued under the Inducement Plan to one share.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.